1 Characteristics of Pediatric Antidepressant Trials Gregory M. Dubitsky, MD Division of Neuropharmacological Drug Products FDA.

Slides:

Advertisements

Similar presentations

Antiepileptic Drugs and Suicidality: Background Evelyn Mentari, M.D., M.S. Clinical Safety Reviewer Division of Neurology Products/CDER Food and Drug Administration.

Advertisements

New England Journal of Medicine October 18;367: Relapse Risk after Discontinuation of Risperidone in Alzheimer’s disease Molly Moncrieff.

THE DIABETES PREVENTION PROGRAM RESEARCH GROUP*

Suicidality and Anti-epileptic Drugs: Status of Clinical Trial Data Analysis Evelyn Mentari, MD, MS Division of Neurology Products.

1 Timing and Duration of Relapse Prevention Trials in Psychiatric New Drug Development David Michelson, M.D. Executive Director, Neuroscience Medical Research.

Journal Club Alcohol, Other Drugs, and Health: Current Evidence March–April 2015.

Methylphenidate Transdermal System (MTS): Safety Issues Robert Levin, M.D. Medical Officer Division of Psychiatry Products Center for Drug Evaluation and.

Réunion Ambulatoires SAS,  Similarly, a statistically significant MADRS reduction over time was found (F=156.2, p 800 mg/day) and low (

Studying treatment of suicidal ideation & attempts: Designs, Statistical Analysis, and Methodological Considerations Jill M. Harkavy-Friedman, Ph.D.

1 Lotronex ® (alosetron HCl) Tablets Risk-Benefit Issues Victor F. C. Raczkowski, M.D. Director, Division of Gastrointestinal and Coagulation Drug Products.

1 Informative Studies of New Therapeutic Agents in Major Depression, GAD & Panic W Z Potter, M.D., PhD. Merck Research Laboratories.

1 One Year Post Exclusivity Adverse Event Review as Mandated by the Best Pharmaceuticals for Children Act Presented at the Psychopharmacologic Drugs Advisory.

Clinical Trials. What is a clinical trial? Clinical trials are research studies involving people Used to find better ways to prevent, detect, and treat.

What FDA Failed to Disclose 1991, 2006 Vera Hassner Sharav Alliance for Human Research Protection.

Continuity Clinic Depression. Continuity Clinic Objectives.

Frequency and type of adverse events associated with treating women with trauma in community substance abuse treatment programs T. KIlleen 1, C. Brown.

Suicide Risk and Antidepressants. Background 1990 Case reports 2003 Advisory: pediatric patients 2004 Warning: children and adolescents 2005 Advisory:

 Major depressive disorder (MDD) is a debilitating condition that has been increasingly recognized among youth  Prevalence of current or recent depression.

Treatment for Adolescents With Depression Study (TADS)

Major Depressive Disorder Natalie Gomez Psychology Period 1.

IzBen C. Williams, MD, MPH Instructor. Lecture - 8 MOOD DISORDERS.

Suicide Risk Assessment. Thoughts, myths, questions about suicide 1.Is suicide a form of manipulation? 2.Will asking about suicide lead to suicidality?

Antidepressants and Suicidality in Adults: Statistical Evaluation Mark Levenson, Ph.D.* and Chris Holland, M.S. Statistical Safety Reviewers Quantitative.

Pediatric Psychopharmacology National Institute of Mental Health.

1 Antidepressants and Suicidality in Adults: Data Overview M. Lisa Jones MD, MPH Medical Reviewer Division of Psychiatry Products Psychopharmacologic Drugs.

Alan Breier, M.D. Leader, Zyprexa Product Team Lilly Research Fellow Professor of Psychiatry, Indiana University School of Medicine Adjunct Associate of.

CCTN September 6 th, Recent Scientific Publications from the Clinical Trials Network David Liu, M.D. (CTN-0029) Harold Perl, Ph.D. (CTN-0015) Paul.

Jeffrey Jonas, MD Vice President CNS - Forest Research Institute Citalopram and Escitalopram Pediatric Safety Data.

Plans for Analysis of Patient Level Data for Pediatric Studies Psychopharmacologic Drugs Advisory Committee and Pediatric Subcommittee of the Anti-Infective.

1 Proton-Pump Inhibitor (PPI) Template for Pediatric Written Requests Pediatric Advisory Subcommittee of the Anti- Infective Drug Advisory Committee Hugo.

Antidepressants and Suicide Risk in Children and Adolescents: Weighing the Evidence Jill A. Morris, PA-S.

RevMan for Registrars Paul Glue, Psychological Medicine What is EBM? What is EBM? Different approaches/tools Different approaches/tools Systematic reviews.

Cardiovascular Risk and NSAIDs Arthritis Advisory Committee Meeting November 29, 2006 Sharon Hertz, M.D. Deputy Director Division of Analgesia, Anesthesia,

DIVISION OF REPRODUCTIVE AND UROLOGIC PRODUCTS Physician Labeling Rule Lisa Soule, M.D.

FDA Hearing on Suicide and Antidepressants Presentation by Charles F. Reynolds, III, MD UPMC Professor of Geriatric Psychiatry University of Pittsburgh.

MPH Label: An opportunity Good that FDA is considering a clarification of the MPH label for safety US should invest more in safety monitoring Problems.

Sertraline Use in Pediatric Population: A Risk Benefit Discussion Steven J. Romano, MD September 13, 2004 Steven J. Romano, MD September 13, 2004 Joint.

CLINICAL EFFICACY TESTING for NASAL DRUGS Mary M. Fanning, M.D., Ph.D. Associate Director for Medical Affairs Office of Generic Drugs, FDA June 4, 1999.

Results of the Analysis of Suicidality in Pediatric Trials of Newer Antidepressants Psychopharmacologic Drugs Advisory Committee and the Pediatric Advisory.

Quiz 1: October 12, Next Thursday 20 m.c. questions –Emphasis on concrete details, can come from text, or interface of text and lectures 40 points of short.

Effectiveness of Cognitive Behavioral Therapy and Selective Serotonin Reuptake Inhibitors in Adolescents with Depression Megan Boose, PA-S Evidence Based.

Long-Term Efficacy Data for Psychiatric Drugs Thomas Laughren, M.D. Director, Division of Psychiatry Products (HFD-130) PDAC Meeting (Oct 25, 2005)

Effects of Initial Dosing Strategies of Duloxetine on Tolerability and Efficacy in Patients with Major Depressive Disorder David Dunner, MD 1 (sponsor);

1 International Society for CNS Clinical Trials and Methodology FDA Advisory Committee Meeting Proposed Requirement for Long-Term Data to Support Initial.

Effect of Rosiglitazone on the Risk of Myocardial Infarction And Death from Cardiovascular Causes Alternative Interpretations of the Evidence George A.

Augmentation of Exposure-Based Cognitive Behavioral Therapy with D-cycloserine in Patients with Panic Disorder Sean Donovan, Meenakshi Shelat, Corrinne.

FRagmin® and Fast Revascularization during InStablity in Coronary artery disease FRISC II.

Modafinil for the Treatment of ADHD Paul J. Andreason, MD Acting Deputy Director Division of Psychiatry Products Center for Drug Evaluation and Research,

Moskowitz CH et al. Proc ASH 2014;Abstract 673.

Clinical Trials - PHASE II. Introduction  Important part of drug discovery process  Why important??  Therapeutic exploratory trial  First time in.

Safety, Efficacy and Duration of Effect of RT002, a Botulinum Toxin Type A for Injection, to Treat Glabellar Lines: The Phase 2 BELMONT Study Authors:

Efavirenz Use Not Associated With Depressive Episodes, According to Analysis of Randomized Clinical Trial Outcomes Slideset on: Journot V, Chene G, De.

Once-Daily Celecoxib Effective for Preventing Sporadic Colorectal Adenomas Slideset on: Arber N, Rácz I, Spicak J, et al. Chemoprevention of colorectal.

1 Psychopharmacologic Drugs Advisory Committee and Pediatric Subcommittee of the Anti-Infective Drugs Advisory Committee February 2, 2004 Office of Drug.

1 Regulatory Background on Antidepressants and Suicidality in Pediatric Patients Thomas Laughren, M.D. Team Leader, Psychiatric Drug Products Group Division.

CHEST 2013; 144(3): R3 김유진 / Prof. 장나은. Introduction 2  Cardiovascular diseases  common, serious comorbid conditions in patients with COPD cardiac.

Number Needed To Treat (NNT)

Copyright © 2010 American Medical Association. All rights reserved.

Efficacy of Paroxetine (Paxil) in the Treatment of Adolescent Major Depression: A Randomized, Controlled Trial Case Study presented by: carlo carandang,

Major Depressive Disorder: Latest Clinical Update

Tools for Screening and Measuring Progress

What Is Major Depressive Disorder (MDD)?

The Patient Journey to Remission in MDD: A Collaborative Approach

What Would You Do in This Case of MDD?

Scientific Update.

Copyright Notice This presentation is copyrighted by the Psychopharmacology Institute. Subscribers can download it and use it for professional use. The.

New Trends in Treatment for Major Depressive Disorder

Communicating With Your Patients About Major Depressive Disorder

Widening the Options for Major Depressive Disorder

How Should We Select and Define Trial Estimands

Presentation transcript:

1 Characteristics of Pediatric Antidepressant Trials Gregory M. Dubitsky, MD Division of Neuropharmacological Drug Products FDA

2 Objective Descriptive only. Will not address effect of study characteristics on suicidality risk: See Dr. Hammad’s Presentation

3 Study Pool 23 placebo-controlled studies conducted between 1984 and drugs. 5 indications (major depression, OCD, GAD, SAD, ADD).

4 Common Design Features Randomized. Double-blind. Placebo-controlled. Parallel group. Flexible-dose.

5 Basic Study Design See Handout: Table 1 Drug, study, indication. Age range. Number of patients in analysis by TX. Duration of double-blind TX. Protocol-specified dose range.

6 Screening and Key Exclusionary Criteria See Handout: Table 2 Extensive diagnostic screening. Placebo lead-in preceding DB TX (and exclusion of placebo responders). Exclusionary criteria: H/O treatment resistance, current suicide risk, H/O suicide attempt, bipolar disorder, family H/O bipolar disorder.

7 Other Study Features (see Appendix to my review) study dates/location/number of centers. stratified randomization by age group. exclusionary criteria: -homicidal risk. -psychotic symptoms. -alcohol/drug abuse. -borderline personality disorder. -eating disorder.

8 Notable Study Differences Prozac HCCJ (MDD): small & terminated early. One active-control study: - Paxil 329 (MDD) (imipramine). Two studies included inpatients: - Celexa (MDD) & Wellbutrin 75 (ADD). Three studies used extensive DX screening: -Prozac X065 & HCJE; Paxil 329 (all MDD).

9 Post-DB Phase TX Options Variable across trials: Taper of acute TX (8 trials). Abrupt D/C (7 trials). Open-label TX (5 trials). Continued DB TX (3 trials). Also variable within trials: e.g., Paxil 329 (MDD) - responders continued DB TX, non-responders tapered. Variable follow-up hindered W/D effect analysis.

10 No study was specifically designed to assess suicidality. suicide attempts and ideation detected only by routine safety monitoring: -treatment-emergent adverse events. -suicide-related items on depression scales (CDRS-R, K-SADS, HAM-D, and MADRS). AE description often incomplete or vague.

11 Conclusions Potential influence of study design characteristics on suicide risk: See Dr. Hammad’s analysis.